TABLE 1.

Study, Patient and Treatment Characteristics of Included Randomized Controlled Trials of Selective Serotonin Norepinephrine Reuptake Inhibitors (SSNRIs) and Selective Serotonin Reuptake Inhibitors (SSRIs) in Children and Adolescents with Generalized, Social and/or Separation Anxiety Disorders.

Author	Publicati on Year	Recruitm ent Start Year	Fundin g	Grou p, N	Durati on, wks	Sex % male	Age rang e, years	Medicatio n	Outco me measur e	Endpoi nt dose, mg/day	Maxim um dose, mg/day	Hig h dose SSR I	Medicati on- Placebo Attrition differen ce
Rynn et al.12	2001	NR	Federal	11 11	9	67	5–17	Sertraline	HAMA	50	50	No	9.1%
Birmaher et al.17	2003	1997	Federal	37 1137	12	46	7–17	Fluoxetine	PARS	20	20	No	8%
RUPP14	2001	1997	Federal	63 1165	8	51	6–17	Fluvoxamine	PARS	4.0±2.2b	300	Yes	6%
March et al.13	2007	2003	Industry	137 11148	16a	44	8–17	Venlafaxine ER	SASCA	142	225	N/A	8.0%
Rynn et al.11	2007	2000	Industry	157 11163	8	58	6–17	Venlafaxine ER	PARS	NR	225	N/A	1.6%
Walkup et al.15	2008	2003	Federal	133 1176	12	53	7–17	Sertraline	PARS	133	200	Yes	1.4%
Wagner et al.18	2004	1999	Industry	163 11156	16a	50	8–17	Paroxetine	PARS	32.6	50	Yes	9.4%
Strawn et al.16	2015	2010	Industry	135 11137	10	47	7–17	Duloxetine	PARS	53.6	120	N/A	<1%
Geller et al.71	2007	2003	Industry	87 1189	12	65	7–17	Atomoxetine	PARS	1.3b	120	N/A	1.7%

Note: DBPCT = double blind, placebo-controlled trial; HAM-A = Hamilton Anxiety Rating Scale; PARS = Pediatric Anxiety Rating Scale; SAS-CA = Social Anxiety Scale for Children and Adolescents; pbo = placebo; NR = not reported

^aThis was a 16-week trial; however, 12-week data were used for the analyses described herein.

^bmg/kg/day, rather than mg/day.